All In Biotech

Drug Trial Radar · NCT04085172

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

396

Actual

Start

Sep 18, 2019

Primary completion

Sep 2, 2025

Study completion Sep 2, 2025

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Sep 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

  • Guanfacine hydrochloride (TAK-503)Drug

    Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.

  • Atomoxetine hydrochlorideDrug

    Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.

  • PlaceboOther

    Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change From Baseline in the Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI) Task at Week 18Time frame: At Baseline, Week 18
  2. Part A: Change From Baseline in the CANTAB RTI Task at Week 49Time frame: At Baseline, Week 49
  3. Part B: Change From Baseline in the CANTAB RTI Task at Week 49Time frame: At Baseline, Week 49

Locations

50 sites in 9 countries. Site status is shown where the registry gives one.

  • Harmonex Neuroscience Research

    Dothan, Alabama

  • Advanced Research Center, Inc.

    Anaheim, California

  • Sun Valley Research Center, Inc.

    Imperial, California

  • Alliance Research

    Long Beach, California

  • PCSD Feighner Research

    San Diego, California

  • Homestead Medical Research

    Homestead, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Care Research Center, Inc.

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • AMR Conventions Research, Ltd

    Naperville, Illinois

  • Collective Medical Research LLC

    Prairie Village, Kansas

  • Qualmedica Research, LLC

    Bowling Green, Kentucky

  • Qualmedica Research, LLC

    Owensboro, Kentucky

  • Alivation Research, LLC

    Lincoln, Nebraska

  • Center for Psychiatry and Behavioral Medicine, Inc.

    Las Vegas, Nevada

  • University of Cincinnati

    Cincinnati, Ohio

  • Cutting Edge Research Group

    Oklahoma City, Oklahoma

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee

  • Family Psychiatry of The Woodlands

    The Woodlands, Texas

  • Clinical Research Partners, LLC

    Petersburg, Virginia

  • LKH-Klinikum Graz

    Graz, Austria

  • Medizinische Universtität Wien

    Vienna, Austria

  • UZ Brussel

    Brussels, Belgium

  • UPC KU Leuven Afdeling Kinderpsychiatrie ADHD-raadpleging

    Leuven, Belgium

  • Foyer Saint Francois

    Namur, Belgium

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Zentralinstitut fuer Seelische Gesundheit

    Mannheim, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Koeln

    Cologne, North Rhine-Westphalia, Germany

  • Rheinhessen-Fachklinik Mainz

    Mainz, Rhineland-Palatinate, Germany

  • EB FlevoResearch

    Almere Stad, Netherlands

  • EB UtrechtResearch

    Utrecht, Netherlands

  • Hospital de Cascais - Dr. José de Almeida

    Alcabideche, Portugal

  • Centro Clinico Academico 2CA Associacao Braga, Hospital de Braga Piso 1, Ala E

    Braga, Portugal

  • Centro Hospitalar Universitario Cova da Beira, E.P.E

    Covilha, Portugal

  • Hospital da Senhora da Oliveira Guimarães

    Guimarães, Portugal

  • Hospital CUF Descobertas

    Lisbon, Portugal

  • Centro Materno Infantil do Norte (CMIN) Centro Hospitalar Universitario do Porto

    Porto, Portugal

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Clinica Dr. Quintero

    Madrid, Spain

  • Hospital Infanta Leonor

    Madrid, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.